VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Interventions
- DRUG: pegylated liposomal doxorubicin (PLD)
- DRUG: VTX-2337
- DRUG: Placebo
Sponsor
Celgene
Collaborators